MAIA MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (MAIA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: September 14, 2026 , by Vitoc Vlad .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Vitoc Vlad | Chief Executive Officer | Buy | 73,000 | $1.37 | $100.0K | 1,049,121 | |
| Guerrero Ramiro | Director | Buy | 46,620 | $1.35 | $62.9K | 735,701 | |
| Guerrero Ramiro | Director | Buy | 78,239 | $1.39 | $108.8K | 689,081 | |
| Guerrero Ramiro | Director | Buy | 8,931 | $1.39 | $12.4K | 610,842 | |
| Guerrero Ramiro | Director | Buy | 1,794 | $1.33 | $2.4K | 601,911 | |
| Guerrero Ramiro | Director | Buy | 11,899 | $1.37 | $16.3K | 600,117 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.